On May 28, China's market regulator said on Sunday it had fined two pharmaceutical companies for monopolistic behaviour.
It fined Grand Pharmaceutical 136 million yuan ($19.68 million) and confiscated 149 million yuan of "illegal revenue" for entering into a monopolistic deal with Wuhan Healcare Pharmaceuticals.
The regulator fined Wuhan Healcare Pharmaceuticals 4.13 million yuan and confiscated slightly over 30 million yuan of its revenue.
Source: Reuters
